Pediatric GLP-1 Prescriptions Show Stark Increase in Tampa-St. Petersburg Area
In the Tampa-St. Petersburg (Sarasota) area, GLP-1 prescriptions for children have seen an increase of over 30,000% since 2019, particularly for those with obesity-related conditions like high cholesterol or sleep apnea.
Tampa St. Petersburg, FL, September 8, 2026 —
The Tampa-St. Petersburg (Sarasota) region has experienced a significant surge in the prescription of Glucagon-like peptide-1 (GLP-1) medications for pediatric patients. Data indicates an increase of over 30,000% in these prescriptions since 2019.
This notable rise is primarily observed among children diagnosed with obesity-related health conditions. Conditions frequently cited include high cholesterol and sleep apnea, which are often linked to excess weight.
GLP-1 medications, originally developed for type 2 diabetes management, have gained wider use for weight management in both adult and, more recently, pediatric populations. The dramatic percentage increase suggests a growing trend in utilizing these pharmaceutical interventions for managing childhood obesity and its associated comorbidities in the specified geographic area.
Specific details regarding the absolute number of prescriptions, the age range of the children involved, or the specific GLP-1 medications prescribed were not provided in the summary. Additionally, information concerning the prescribing physicians, healthcare systems, or any regulatory reviews related to this trend was not available. The timeline for this increase covers the period from 2019 to the present, highlighting a shift in treatment approaches for pediatric weight-related health issues over the last several years.
Story summarized from the original created by Stephanie Sokol on www.wfla.com, see more information here.
